Alzheimer disease (AD) is the most common type of dementia and a growing public health concern. Its estimated prevalence in the United States is 5.2 million cases and is projected to exceed 13 million cases by 2050.1 With no cure available, therapy is palliative via modulation of acetylcholine and glutamate. Current treatment patterns favor cholinesterase inhibitors and N-methyl-d-aspartate (NMDA) receptor antagonists, respectively.2
Feng MT, Price FW, McKee Y, Price MO. Memantine-Associated Corneal Endothelial Dysfunction. JAMA Ophthalmol. 2015;133(10):1218–1220. doi:10.1001/jamaophthalmol.2015.2476
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: